Journal ArticleDOI
Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Ronald C. Walker,Bart Barlogie,Jeffrey Haessler,Guido J Tricot,Elias Anaissie,John D. Shaughnessy,Joshua Epstein,Rudy Van Hemert,Eren Erdem,Antje Hoering,John Crowley,Ernest Ferris,Klaus Hollmig,Frits van Rhee,Maurizio Zangari,Mauricio Pineda-Roman,Abid Mohiuddin,Shmuel Yaccoby,Jeffrey Sawyer,Edgardo J. Angtuaco +19 more
Reads0
Chats0
TLDR
MRI is a more powerful tool for detection of FLs than is MBS and is recommended that, in addition to MBS, MRI be used routinely for staging, prognosis, and response assessment in myeloma.Abstract:
Purpose Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs). Patients and Methods Both baseline MBS and MRI were available in 611 of 668 myeloma patients who were treated uniformly with a tandem autologous transplantation–based protocol and were evaluated to determine their respective merits for disease staging, response assessment, and outcome prediction. Results MRI detected focal lesions (FLs) in 74% and MBS in 56% of imaged anatomic sites; 52% of 267 patients with normal MBS results and 20% of 160 with normal MRI results had FL on MRI and MBS, respectively. MRI- but not MBS-defined FL independently affected survival. Cytogenetic abnormalities (CAs) and more than seven FLs on MRI (MRI-FLs) distinguished three risk groups: 5-year survival was 76% in the absence of both more than seven MRI-FLs and CA (n = 276), 61% in the presence of one MRI-FL (n = 262), and 37% in...read more
Citations
More filters
Journal ArticleDOI
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar,Meletios A. Dimopoulos,Antonio Palumbo,Joan Bladé,Giampaolo Merlini,Maria-Victoria Mateos,Shaji Kumar,Jens Hillengass,Efstathios Kastritis,Paul G. Richardson,Ola Landgren,Bruno Paiva,Angela Dispenzieri,Brendan M. Weiss,Xavier Leleu,Sonja Zweegman,Sagar Lonial,Laura Rosiñol,Elena Zamagni,Sundar Jagannath,O. Sezer,Sigurdur Y. Kristinsson,Jo Caers,Saad Z. Usmani,Juan José Lahuerta,Hans Erik Johnsen,Meral Beksac,Michele Cavo,Hartmut Goldschmidt,Evangelos Terpos,Robert A. Kyle,Kenneth C. Anderson,Brian G.M. Durie,Jesús F. San Miguel +33 more
TL;DR: The disease definition of multiple myeloma is updated to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions), and specific metrics that new biomarkers should meet for inclusion in the disease definition are provided.
Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Journal ArticleDOI
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Twyla Bartel,Jeff Haessler,Tracy Brown,John D. Shaughnessy,Frits van Rhee,Elias Anaissie,Terri Alpe,Edgardo J. Angtuaco,Ronald C. Walker,Joshua Epstein,John Crowley,Bart Barlogie +11 more
TL;DR: The results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy.
Journal ArticleDOI
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
Elena Zamagni,Francesca Patriarca,Cristina Nanni,Beatrice Anna Zannetti,Emanuela Englaro,Annalisa Pezzi,Paola Tacchetti,Silvia Buttignol,Giulia Perrone,Annamaria Brioli,Lucia Pantani,Carolina Terragna,Francesca Carobolante,Michele Baccarani,Renato Fanin,Stefano Fanti,Michele Cavo +16 more
TL;DR: PET/CT involvement at diagnosis, after novel agent-based induction and subsequent ASCT is a reliable predictor of prognosis in MM patients and persistence of SUV > 4.2 after TD induction was an early predictor for shorter PFS.
Journal ArticleDOI
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.
Meletios A. Dimopoulos,Evangelos Terpos,Raymond L. Comenzo,Patrizia Tosi,Meral Beksac,Orhan Sezer,David S. Siegel,Henk M. Lokhorst,Shaji Kumar,S V Rajkumar,Ruben Niesvizky,Lia A. Moulopoulos,Brian G.M. Durie +12 more
TL;DR: Bone scintigraphy has no place in the routine staging of myeloma, whereas sequential dual-energy X-ray absorptiometry scans are not recommended, and Positron emission tomography/CT or MIBI imaging are also not recommended for routine use in the management of Myeloma patients.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
TL;DR: Initial staging can be quantitatively related to followup using tumor cell mass changes calculated from changes in M‐component production, and should lead to improved study design and analysis in large clinical trials of therapy for multiple myeloma.
Journal ArticleDOI
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators
Ted Gooley,Ted Gooley,Wendy M. Leisenring,Wendy M. Leisenring,John Crowley,John Crowley,Barry E. Storer,Barry E. Storer +7 more
TL;DR: A representation of each estimate in a manner not ordinarily seen is presented, each representation utilizing the concept of censored observations being 'redistributed to the right' to allow a more intuitive understanding of each estimates.